+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Age: 65Years - 80Years
All Genders
ID07158905

Randomized Study of AV-1980R Vaccine Safety and Immune Response in Adults 65-80 With Preclinical Alzheimers Disease

Led by Institute for Molecular Medicine · Updated on 2026-08-21

48

Participants Needed

6

Research Sites

17 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating AV-1980R, an investigational vaccine targeting pathological tau proteins, in adults aged 65 to 80 years with preclinical Alzheimers disease. This Phase 1, randomized, double-blind, placebo-controlled study aims to assess the safety, tolerability, and immune response elicited by the vaccine in cognitively unimpaired participants who have biomarker evidence of early Alzheimers pathology. Participants will be randomly assigned in a 31 ratio to receive one of three ascending doses of AV-1980R 20 g, 60 g, or 180 g or placebo. The vaccine or placebo is given as three intramuscular injections at Weeks 0, 4, and 38. The study includes follow-up visits through Week 58 to monitor participants. During the study, participants will undergo safety assessments including monitoring for adverse events, vital signs, ECG, laboratory tests, neurological exams, and brain MRI scans. Researchers will measure immune responses such as anti-tau antibody levels and T-cell activity, along with exploratory evaluations of plasma Alzheimers biomarkers, tau PET imaging, and cognitive function. The total participation period spans from screening through Week 58, focusing on vaccine safety and immune effects.

CONDITIONS

Brief Title

AV-1980R (Tau Vaccine) in Preclinical Alzheimer's Disease (TAURUS-1980)

Research Team

R

Roman Kniazev

A

Anahit Ghochikyan

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here